Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

The European Union has slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog

The Independent UK

Ramarketing signals Canadian expansion with new Toronto office

It is the latest international office opening for the Newcastle firm that is backed by private equity house Northedge Capital

Birmingham Post

Cheap Air Sensor Detects Covid In 5 Minutes, Opening Door To Real-Time Virus Surveillance

New compact device differentiates between coronavirus, flu, and other infections, allowing for immediate action

Zenger

From analysis to the latest developments in health,
read the most diverse news in one place.

Retailers seek to shake up clinical trials business

Big retailers see a growth opportunity tapping their huge customer bases to recruit participants into clinical trials.

Axios

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK

Scottish government says it wants to make drug possession legal

But the UK government has already poured cold water on the idea

Nottingham Post

3 July Pharma Picks for Profit

The pharma industry performs relatively well during downturns due to inelastic demand for its products and services. Therefore, fundamentally strong pharma stocks Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) might be profitable buys. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Scottish government wants to decriminalise drug possession

But the UK government has already poured cold water on the idea

Wales Online

Buy These 3 Pharma Stocks in July

The pharmaceutical industry looks well-positioned for long term growth due to the globalization of the industry, increasing investments to develop life-saving drugs, rise in chronic diseases, and a rapidly aging population. To that end, it could be wise to buy fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Ironwood Pharmaceuticals (IRWD),…

StockNews.com

Scottish reforms to decriminalise personal drug use knocked down within an hour

Scottish drugs minister Elena Whitham said ‘criminalisation increases the harms people experience. Criminalisation kills’.

The Independent UK

Drugs minister ‘terrified’ of potential impact of failure to reform policy

Downing Street re-committed to its ‘tough’ stance on drugs as the Scottish Government called for decriminalisation of personal use.

The Independent UK

Ministers cannot be the last to know when inward investors like Zimmer Biomet pull out of Wales

A more constructive approach to managing relationships with major employers is important in the future especially if they are in receipt of public funding.

Birmingham Post

RSS’s pharma body writes to Health Ministry criticising risk-based inspections, backtracks later

In a strongly worded letter to the Union Health Ministry, the Rashtriya Swayamsewak Sangh- (RSS) backed Laghu Udyog Bharati, which represents over 300 micro and small industries across India, has said the Union government’s risk-based inspections (RBI) on pharma companies were draconian and have been a huge discouragement to the…

The Hindu

AbbVie (ABBV) vs. Pfizer (PFE) - Which Pharma Stock Comes out on Top?

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Moderna signs deal to make mRNA vaccines for Chinese market

Moderna Inc. will push toward producing messenger RNA vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.

The Hindu

Regulation for all medical devices from October 1, says DCGI

India is on course to introduce regulations governing all the medical devices in the country on October 1, Drugs Controller General of India Rajeev Singh Raghuvanshi said at iPhex 2023

StockNews.com

Which Pharma Stock Is the Better July Pick: Johnson & Johnson (JNJ) or Curaleaf Holdings (CURLF)?

On the backs of increasing medical requirements amid the soaring incidence of chronic diseases, the pharmaceutical industry’s outlook radiates promise. Given this backdrop, let us compare pharma stocks Johnson & Johnson (JNJ) and Curaleaf Holdings (CURLF) to discover which one of these could be worth buying in July. Read on….

Zenger

Medicare To Negotiate Drug Prices, Lower Costs

CMS releases guidance on using authority to expand benefits, reduce drug costs, and strengthen Medicare program.

Get all your
news in one place.

100’s of premium titles.
One news app.

AAP

Pharmacies receive $377m medication sweetener

Pharmacies will be paid thousands more to dispense medicines from July 1 as part of a government funding boost.

Tribune News Service

Will lower-cost Humira pharmaceutical options soon be available to patients?

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings?

Tribune News Service

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

StockNews.com

Is Catalyst Pharmaceuticals (CPRX) a Quality Investment?

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) delivered a robust performance in the first quarter of 2023. However, it fell short of analysts’ estimates. Let’s dig into some of its financial metrics to determine whether CPRX is worth buying ahead of the upcoming earnings season.

Wales Online

Deep concern as Zimmer Biomet closure in Bridgend puts 540 jobs at risk

The announcement has left a community in shock

Birmingham Post

Andor Technologies sets sights on £20M of exports with new scientific microscope

The company said the new product represents disruptive technology and will see it break into new markets

The Independent UK

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

1 … 45 46 47 48

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Scottish Government

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.